PDSB 250117 2.50P (PDSB250117P2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

PDSB250117P2500

Watchlist

0.50
0.000.00%

15min DelayClose Jan 6 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

A. G. P. Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Cuts Target Price to $4.5
Moomoo NewsDec 19, 2024 05:31 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
BenzingaDec 18, 2024 06:41 ET
Promising Advancements in Cancer Treatment Drive Buy Rating for PDS Biotechnology
TipRanksDec 18, 2024 06:26 ET · Ratings
Express News | PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
ReutersDec 6, 2024 08:00 ET
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswireDec 6, 2024 08:00 ET
PDS Biotechnology Corporation Announces Key Opinion Leader Event on HPV16-Positive Head and Neck Cancer and Phase 3 Clinical Trial for Versamune HPV
Quiver QuantitativeDec 3, 2024 08:13 ET

Comments

Jaguar8

Oct 22, 2024 07:04

NEWS

$PDS Biotechnology (PDSB.US)$
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
PDS Biotechnology (Nasdaq: PDSB) announced that the rationale and trial design for a study evaluating PDS01ADC in recurrent prostate cancer treatment will be presented at the 12th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2024) in Seoul, South Korea. The pres...

Aladdin Map

Oct 2, 2024 12:29

$PDS Biotechnology (PDSB.US)$ break thurr 4.0 n fly pls 🚀🚀🚀

Jaguar8

Oct 2, 2024 07:05

NEWS

$PDS Biotechnology (PDSB.US)$
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8)
88% (15/17) of patients had a complete metabolic response
IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024
PRINCETON, N...

Trytosaveabit

Oct 2, 2024 07:00

News

$PDS Biotechnology (PDSB.US)$ Reuters
·just
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated With Versamune® Hpv and Chemoradiation

Jaguar8

Sep 16, 2024 06:04

NEWS

$PDS Biotechnology (PDSB.US)$
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77%
11/53 (21%) of patients experienced 90-100% tumor shrinkage
VERSATILE-003 Phase 3 clinical trial planned to begin this year
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"...